Key Takeaways
- Steriles drove the quarter, up 51%: The injectables business hit ~₹108 cr, validating years of R&D and asset investment, while the new softgel line lifted both volume and contribution margin.
- The U.S. build-out is accelerating: 27 state licenses secured, a first ready-to-use bag injectable launching, and 35 niche products under development, but management warns the front-end model will prioritize sustainability over speed.
- A biosimilars pivot is taking shape: The company will outsource from China, do fill-finish in India, and target ROW and second-level regulated markets, explicitly avoiding the U.S. for biologics.
- Growth will moderate from 50%: Management is clear that the Steriles trajectory is not repeatable year-on-year and that older products face order reductions, so the portfolio must widen to offset declines.
- What to watch next quarter: The pace of U.S. state licensing, the launch cadence of ophthalmic and bag injectable products, and any concrete numbers from the Chairman's China trip for biosimilar partnerships.
Steriles & the Injectables Engine
- 51% growth on a lower base: Caplin Steriles delivered ~₹313 cr in operating revenue, ₹61.2 cr EBITDA, and ₹18.7 cr PAT for FY24, slightly exceeding guidance.
- Output nearly doubled: Production rose from 1.6 crore vials last financial year to around 2.7 crore vials, with close to 50% of recent output coming from the Line 5 expansion in Phase 2.
- Revenue mix reflects the model: Roughly 75% product revenue and 25% milestones and profit share, a split management considers commendable because the company does no exclusive deals and very little CMO work.
- Line 6 is nearing readiness: The prefilled syringe and cartridge line is being qualified now, with all qualifications expected to complete in the next month; new peptide injectable products for global markets will be manufactured here.
- Growth trajectory is normalizing: Management acknowledges 50% growth is not sustainable year-on-year and expects to "grow well" but not repeat that pace immediately, with some older products likely to see order reductions.
Paarthipan: "Slight dip here and there is likely to be there in any company, and it's more like a bend if not an end."
U.S. Market Entry & Front-End Strategy
- Licensing is progressing fast: Caplin Steriles U.S.A Inc. has received 27 state licenses out of 50 and is confident of being substantially licensed across nearly all states in the next two to three months.
- First niche launches are imminent: A first ready-to-use bag injectable product, described as a very niche area, will launch very shortly in the U.S.
- Pipeline is deep and deliberate: 35 products are under active development for filing over the next two to three years, with a new focus on very niche global dossier molecules including GLP-1 products for anti-obesity and anti-diabetes.
- Go-to-market will bypass middlemen: Management is evaluating a direct-to-hospital, direct-to-clinic model instead of supplying to GPOs and larger wholesalers, which may result in slower top-line growth but be more sustainable and value-accretive.
- Outsourcing will protect margins: Early-stage discussions are underway with other CMOs to transfer high-volume, low-value products so the company can focus in-house manufacturing only on niche molecules. [4-5]
- Own-label sales are a FY25 exit story: Some sales from the company's own label are expected by the end of FY25, though not meaningful in the first financial year; the following year onwards could show something better.
LatAm Moat & Business Model
- Six small geographies drive 75-80% of revenue: Guatemala is the largest, followed by Nicaragua, El Salvador, Honduras, Dominican Republic, and Ecuador.
- The moat is time, not price: Caplin has been in Central America for 20-21 years, and that presence creates an entry barrier competitors cannot replicate quickly.
- Price disparity is extreme: If Caplin's product is priced at $2, the same generic from MNCs or large Argentine companies is 4-5 times higher, yet chemists will not switch brands for fear of losing customers who ask for Caplin's product by name.
- The model removes intermediaries: The strategy is to go to the last mile, the pharmacy or hospital, and build customer relationships over decades, a model the Chairman contrasts with selling generics in India.
- Chinese competition is not a pharma threat: Chinese companies are moving to Mexico to avoid U.S. trade tariffs but are not entering pharmaceuticals; they are not good at private-market business and marketing compared to Indians.
Paarthipan: "If you want to be a numero uno, even if it is a smaller business, you cannot run faster than a person in the form of a giant. You will only have to run in the opposite direction."
Biosimilars & the China Pivot
- The model is asset-light fill-finish: Caplin plans to import biological products, insulin, biosimilars, and peptides in bulk from China, complete fill-finish at its own injectable facility in India, and export to countries where it already operates.[7-8]
- Target markets exclude the U.S.: The company will focus on ROW markets, which can be done with Phase 1 trials, and second-level regulated markets like Mexico, Brazil, and South Africa; the U.S. is described as a "place for monopolies and near-monopolies."
- Timeline is long and uncertain: Phase 3 clinical trials are needed, and management estimates it may take two to three years before meaningful business materializes, irrespective of market size.[7-8]
- Investment scale is material: The opportunity is good but requires ₹500-600 crores for companies of Caplin's size; exact investment figures will be known only after the Chairman's trip to China.
- The Chairman is traveling to China: He will meet large companies to structure future business on an asset-light model for biological products.
Facilities, Capex & Automation
- Softgel line is running near full capacity: The new line commissioned in April is operating at roughly 90-95% of enhanced capacity, facilitating both volume and contribution margin increases because these are niche products.
- INVIMA audit cleared: The Colombian regulator concluded its audit at the CP-1 facility in Pondicherry successfully for softgel capsules, opening the path to reach products in Mexico, Chile, and other major LatAm geographies.
- Caplin One Labs is progressing: The tablet and capsule section of the oncology facility is complete; injectables commissioning is in progress and will be completed in 10-12 months, after which the company plans an EU audit and subsequently a U.S. FDA inspection.
- API facilities are on track for 2025: The API facility in Vizag and the Onco API facility remain work-in-progress but are sure to complete in 2025.
- Automation is advancing: QC and microbiology are already fully automated; a software partner has been engaged to convert all manual logbooks to electronic logbooks in the next few months, a steppingstone toward electronic batch manufacturing and packing records.
- Residual capex is ~₹250-300 crores: 50-55% of total capex is already completed, excluding API; the remainder will be spent over the next couple of years on the OSD facility, API facility, injectable equipment, and additional lines in CP-1.
- OPEX for new facilities is manageable: The initial period after the injectable facility is completed will require roughly ₹1-2 crores per month maximum.
Paarthipan: "Be uncomfortable for a year or two to be comfortable for the rest of the years to come."
Cash, Capital Allocation & Acquisitions
- Cash is held for three purposes: Future meaningful acquisitions, especially distribution companies in bigger geographies; project completion; and Phase 3 clinical trials for biological products.
- Acquisition target is distribution, not manufacturing: The company wants a distribution company that would provide last-mile market intelligence in larger markets.
- Timing is entirely opportunistic: An acquisition could happen after one year or maybe after three years, depending on opportunities; no commitment was given.
- Shareholder returns are undecided: No decision has been taken on dividend, buyback, or bonus; management will check with directors and take a call.
Paarthipan: "You know there is saying, people always say 'Top line is vanity, bottom line is sanity, cash is king'. And we keep the cash for future acquisition."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| U.S. state licensing | Substantially licensed across close to all 50 states | Next 2-3 months |
| Line 6 qualification | Prefilled syringe and cartridge line fully qualified | Next 1 month |
| Caplin One Labs injectables | Commissioning completed, then EU audit and U.S. FDA inspection | 10-12 months for commissioning |
| API facilities completion | API facility in Vizag and Onco API | 2025 |
| Mexico own-warehouse entry | Once 25-30 products registered, start own warehouse and private market | ~2 years from now |
| Biological products business | Fill-finish model generating good business irrespective of market size | 2-3 years from now[7-8] |
| Caplin Onco profitability | Become profitable | ~6 quarters |
| U.S. own-label sales | Some sales from own label by end of FY25, meaningful later | FY25 exit / FY26 onwards |
| Residual capex | ~₹250-300 crores across OSD, API, injectable equipment, CP-1 lines | Next couple of years |
| OSD facility for U.S. | Construction start on second facility on purchased land | ~6 months from now |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue growth | 15.5% YoY |
| PAT growth | 22.4% YoY |
| PAT margin | 26.19%, above guided range of 24.5% to 25% |
| Contribution margin increase | ~3% YoY, overall contribution increase of ~₹166 cr |
| EBITDA contribution from revenue increase | ₹122 cr of the ₹176 cr increase in contribution and other income flowed directly to EBITDA |
| Cash and cash equivalents | ~₹910 cr as of March 2024 |
| Cash flow from operations | ₹318 cr, ~60% of PBT |
| Caplin Steriles revenue | ~₹313 cr for FY24, over 50% growth YoY |
| Caplin Steriles EBITDA | ₹61.2 cr for FY24 |
| Caplin Steriles PAT | ₹18.7 cr for FY24 |
| Caplin Steriles revenue split | ~75% product revenue, 25% milestones and profit share |
| Caplin Steriles output | ~2.7 crore vials in FY24, up from 1.6 crore vials in FY23 |
| Approved ANDAs | 21 approved, 14 under review |
| U.S. state licenses obtained | 27 out of 50 |
| Products under active development | 35 to be filed over next two to three years |
| Softgel capacity utilization | 90% to 95% of enhanced capacity |
| Caplin Onco loss for FY24 | ₹2.82 cr, operations commenced 15 March 2024 |
| Pending CAPEX | ~₹250–300 cr over next couple of years |
| Capital work in progress | ₹116.6 cr |
| Product registrations from India | 4,485 |
| Product registrations from China | 275 |
| China-sourced business mix | 20% of total, down from 60% historically |
| LatAm concentration | 75%–80% of total business from six smaller geographies |